

Federica Morano

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4936248/publications.pdf>

Version: 2024-02-01

40
papers

2,000
citations

535685

17
h-index

325983

40
g-index

40
all docs

40
docs citations

40
times ranked

4201
citing authors

#	ARTICLE	IF	CITATIONS
1	Variant allele frequency in baseline circulating tumour DNA to measure tumour burden and to stratify outcomes in patients with RAS wild-type metastatic colorectal cancer: a translational objective of the Valentino study. <i>British Journal of Cancer</i> , 2022, 126, 449-455.	2.9	15
2	Reinduction of an Anti-EGFR-based First-line Regimen in Patients with <i>RAS</i> Wild-type Metastatic Colorectal Cancer Enrolled in the Valentino Study. <i>Oncologist</i> , 2022, 27, e29-e36.	1.9	3
3	Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O ⁶ -Methylguanineâ€“DNA Methyltransferaseâ€“Silenced Metastatic Colorectal Cancer: The MAYA Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 1562-1573.	0.8	52
4	Epidermal Growth Factor Receptor Inhibition in Epidermal Growth Factor Receptorâ€“Amplified Gastroesophageal Cancer: Retrospective Global Experience. <i>Journal of Clinical Oncology</i> , 2022, 40, 2458-2467.	0.8	9
5	Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer Patients. <i>Cancer Discovery</i> , 2022, 12, 1656-1675.	7.7	48
6	<i>MGMT</i> inactivation as a new biomarker in patients with advanced biliary tract cancers. <i>Molecular Oncology</i> , 2022, 16, 2733-2746.	2.1	2
7	Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With <i>RAS/BRAF</i> Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO. <i>Journal of Clinical Oncology</i> , 2022, 40, 2878-2888.	0.8	24
8	Impact of early tumor shrinkage and depth of response on the outcomes of panitumumab-based maintenance in patients with <i>RAS</i> wild-type metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2021, 144, 31-40.	1.3	12
9	Optimized EGFR Blockade Strategies in <i>EGFR</i> Addicted Gastroesophageal Adenocarcinomas. <i>Clinical Cancer Research</i> , 2021, 27, 3126-3140.	3.2	11
10	The Added Value of Baseline Circulating Tumor DNA Profiling in Patients with Molecularly Hyperselected, Left-sided Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 2505-2514.	3.2	14
11	Personalized therapeutic strategies in HER2-driven gastric cancer. <i>Gastric Cancer</i> , 2021, 24, 897-912.	2.7	6
12	<i>EGFR</i> Amplification in Metastatic Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1561-1569.	3.0	12
13	Health-related quality of life in patients with <i>RAS</i> wild-type metastatic colorectal cancer treated with panitumumab-based first-line treatment strategy: A pre-specified secondary analysis of the Valentino study. <i>European Journal of Cancer</i> , 2020, 135, 230-239.	1.3	11
14	Clinical Behavior and Treatment Response of Epstein-Barr Virus-Positive Metastatic Gastric Cancer: Implications for the Development of Future Trials. <i>Oncologist</i> , 2020, 25, 780-786.	1.9	14
15	Capecitabine and Temozolomide versus FOLFIRI in <i>RAS</i> -Mutated, <i>MGMT</i> -Methylated Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 1017-1024.	3.2	22
16	Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With <i>RAS</i> Wild-Type Metastatic Colorectal Cancer. <i>JAMA Oncology</i> , 2019, 5, 1268.	3.4	70
17	Negative Hyperselection of Patients With <i>RAS</i> and <i>BRAF</i> Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy. <i>Journal of Clinical Oncology</i> , 2019, 37, 3099-3110.	0.8	65
18	Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 3392-3400.	0.8	293

#	ARTICLE	IF	CITATIONS
19	A Comprehensive PDX Gastric Cancer Collection Captures Cancer Cellâ€™s Intrinsic Transcriptional MSI Traits. <i>Cancer Research</i> , 2019, 79, 5884-5896.	0.4	53
20	Benefit from anti-EGFRs in RAS and BRAF wild-type metastatic transverse colon cancer: a clinical and molecular proof of concept study. <i>ESMO Open</i> , 2019, 4, e000489.	2.0	14
21	Whole exome sequencing analysis of urine trans-renal tumour DNA in metastatic colorectal cancer patients. <i>ESMO Open</i> , 2019, 4, e000572.	2.0	27
22	Refining the selection of patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of O6-methylguanine-DNA-methyltransferase. <i>European Journal of Cancer</i> , 2019, 107, 164-174.	1.3	9
23	Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials. <i>British Journal of Cancer</i> , 2018, 118, 955-965.	2.9	17
24	Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study. <i>Clinical Cancer Research</i> , 2018, 24, 1082-1089.	3.2	76
25	Duration of first-line treatment for metastatic colorectal cancer: Translating the available evidence into general recommendations for routine practice. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 131, 53-65.	2.0	12
26	Bilateral parotid gland metastases from gastric signet-ring cell carcinoma. <i>Tumori</i> , 2018, 104, NP10-NP13.	0.6	4
27	Platinum-Fluoropyrimidine and Paclitaxel-Based Chemotherapy in the Treatment of Advanced Anal Cancer Patients. <i>Oncologist</i> , 2017, 22, 402-408.	1.9	31
28	Systemic Chemotherapy as Salvage Treatment for Locally Advanced Rectal Cancer Patients Who Fail to Respond to Standard Neoadjuvant Chemoradiotherapy. <i>Oncologist</i> , 2017, 22, 728-736.	1.9	10
29	ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	183
30	Preoperative Capecitabine, Oxaliplatin, and Irinotecan in Resectable Gastric or Gastroesophageal Junction Cancer: Pathological Response as Primary Endpoint and FDG-PET Predictions. <i>Oncology</i> , 2017, 93, 279-286.	0.9	9
31	Implementation of Extensive Cytoreduction Resulted in Improved Survival Outcomes for Patients with Newly Diagnosed Advanced-Stage Ovarian, Tubal, and Peritoneal Cancers. <i>Annals of Surgical Oncology</i> , 2017, 24, 3396-3405.	0.7	11
32	Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical study. <i>ESMO Open</i> , 2017, 2, e000241.	2.0	10
33	Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth. <i>Nature</i> , 2017, 552, 116-120.	13.7	480
34	Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer. <i>British Journal of Cancer</i> , 2017, 117, 347-352.	2.9	31
35	Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 2414-2422.	3.2	148
36	Perioperative Triplet Chemotherapy and Cetuximab in Patients With RAS Wild Type High Recurrence Risk or Borderline Resectable Colorectal Cancer Liver Metastases. <i>Clinical Colorectal Cancer</i> , 2017, 16, e191-e198.	1.0	12

#	ARTICLE	IF	CITATIONS
37	Treatment of Metastatic Colorectal Cancer Patients ≥75 Years Old in Clinical Practice: A Multicenter Analysis. PLoS ONE, 2016, 11, e0157751.	1.1	17
38	MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in <i>BRAF</i> -Mutated Colorectal Cancer. Cancer Discovery, 2016, 6, 963-971.	7.7	85
39	Incidence of thromboembolic events in patients with locally advanced rectal cancer receiving neoadjuvant chemoradiotherapy. Acta Oncologica, 2013, 52, 187-190.	0.8	12
40	Incidence and risk of pulmonary toxicity in patients treated with mTOR inhibitors for malignancy. A meta-analysis of published trials. Acta Oncologica, 2012, 51, 873-879.	0.8	66